About Sequenta
Sequenta is a company based in San Francisco (United States) founded in 2008 by Malek Faham and Thomas Willis was acquired by Adaptive Biotechnologies in January 2015. Sequenta has raised $43.46 million across 5 funding rounds from investors including Adaptive Biotechnologies, Celgene and Foresite Capital. Sequenta offers products and services including clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics. Sequenta operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter San Francisco, United States
- Founders Malek Faham, Thomas Willis
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sequenta Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$43.46 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Adaptive Biotechnologies
& 4 more
-
Employee Count
Not available
-
Acquired by
Adaptive Biotechnologies
(Jan 07, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sequenta
Sequenta offers a comprehensive portfolio of products and services, including clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics.
NGS-based test for assessing minimal residual disease in trials
Platform for immune receptor data analysis in drug development
Tools for T-cell receptor-based antibody therapies
Funding Insights of Sequenta
Sequenta has successfully raised a total of $43.46M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sequenta
Sequenta has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Adaptive Biotechnologies, Celgene and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology startups and entrepreneurs.
|
Locked | Locked | Locked |
Investor details for Sequenta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sequenta
Investment portfolio details for Sequenta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sequenta
Detailed financials for Sequenta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sequenta Comparisons
Peer comparison for Sequenta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sequenta
Sequenta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of Sequenta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sequenta
Complete news archive for Sequenta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sequenta
Sequenta was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Sequenta is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sequenta is a funded company, having raised a total of $43.46M across 5 funding rounds to date.
Sequenta was founded in 2008 in San Francisco, United States, within the biotechnology sector. Immuno-sequencing technologies are researched and developed for applications in diagnosing and treating cancer, autoimmune disorders, and infectious diseases. A primary diagnostic test was produced to assess minimal residual disease in hematological cancers. Operations centered on these tools until acquisition by Adaptive Biotechnologies in January 2015 for an undisclosed sum.
Sequenta's top competitors include Guardant Health, Foundation Medicine and Forty Seven.
Sequenta offers clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics.
Sequenta has 5 investors. Key investors include Adaptive Biotechnologies, Celgene, Foresite Capital, Mohr Davidow Ventures, and Index Ventures.